



**HAL**  
open science

## Number of initial symptoms is more related to long COVID-19 than acute severity of infection: a prospective cohort of hospitalized patients

Adrien Chan Sui Ko, Alexandre Candellier, Marie Mercier, Cédric Joseph, Jean-Luc Schmit, Jean-Philippe Lanoix, Claire Andrejak

### ► To cite this version:

Adrien Chan Sui Ko, Alexandre Candellier, Marie Mercier, Cédric Joseph, Jean-Luc Schmit, et al.. Number of initial symptoms is more related to long COVID-19 than acute severity of infection: a prospective cohort of hospitalized patients. *International Journal of Infectious Diseases*, 2022, 118, pp.220-223. 10.1016/j.ijid.2022.03.006 . hal-03703107

**HAL Id: hal-03703107**

**<https://u-picardie.hal.science/hal-03703107>**

Submitted on 22 Jul 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Number of initial symptoms is more related to long COVID-**  
2 **19 than acute severity of infection: a prospective cohort of**  
3 **hospitalized patients.**

4 *Chan Sui Ko Adrien<sup>1</sup>, Candellier Alexandre<sup>2</sup>, Mercier Marie<sup>3</sup>, Joseph Cédric<sup>1</sup>, Jean-Luc Schmit<sup>1</sup>*  
5 *Lanoix Jean-Philippe<sup>1</sup>, Andrejak Claire<sup>3</sup>.*

6

7 1. Department of Infectious Diseases, Centre Hospitalier Universitaire Amiens-Picardie,  
8 Amiens, 80054 France

9 2. Department of Nephrology, Centre Hospitalier Universitaire Amiens-Picardie, Amiens  
10 80054 France

11 3. Department of Pneumology, Centre Hospitalier Universitaire Amiens-Picardie,  
12 Amiens 80054 France

13

14 **Word count:** 869

15 **Table:** 1

16 **Figure:** 1

17 **Key words:** COVID-19, persistent symptoms, long covid, risk factor, severity

18 **Disclosures:** none

19 **Corresponding author:**

20 Chan Sui Ko Adrien,

21 Department of Infectious Disease,

22 Centre Hospitalier Universitaire Amiens-Picardie,

23 80054 Amiens,

24 France

25 Email: chansuiko.adrien@chu-amiens.fr

26

27

## Introduction

28 Post-COVID-19 symptoms experienced by many survivors after infection have a  
29 further devastating effect. Reports of risk factor of long COVID-19 are rising but data  
30 including reliable assessment of persistent symptoms by structured face to face follow up  
31 visit are scarce (Halpinet al. 2021). Here we report a study assessing post-COVID-19  
32 associated risk factors in hospitalized patients including those requiring ICU four months  
33 after admission. We provide also data about objective measures of COVID-19 severity e.g.,  
34 oxygen requirement, inflammatory biomarkers and radiological findings.

35

## Methods

36 We conducted a prospective cohort study of hospitalized patients with COVID-19,  
37 discharged from the Amiens Picardie University Hospital, France, from 2<sup>nd</sup> February 2020 to  
38 28<sup>th</sup> December 2020. SARS-CoV-2 infection was confirmed by polymerase chain reaction  
39 (PCR) in nasopharyngeal swab. Clinical, biological, radiological and hospitalization data were  
40 collected from hospital medical records. All patients were assessed by trained physicians  
41 during a face-to-face structured follow-up visits and asked about a list of post-COVID  
42 symptoms. Clinical examination, blood analysis and lung CT-scan was also performed during  
43 this dedicated visit. Long Covid was considered in patients exhibited post-COVID persistent  
44 symptoms 4 months after the hospital admission. Multivariable adjusted logistic regression  
45 models were constructed to identify clinical and hospitalization variables associated with  
46 post-COVID-19 syndrome in a stepwise manner and Poisson regression to identify those  
47 associated with the number of persistent symptoms. All tests were two-sided, and a p-value  
48 less than 0.05 was considered statistically significant. For this study we used data from  
49 SEQCOV cohort, the study protocol was approved by institutional review board and CHU  
50 Amiens-Picardie ethics committee (PI2018\_843\_0049).

## Results

51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74

From 586 discharged patients, a total of 316 patients achieved a four-month structured follow up visit. Patients with follow up evaluation conducted in other hospital or declined (n=138), died (n=34) or with missing data (n=98) were excluded. Two hundred and one (63.6%) of patients had at least one symptom at the follow-up.

The demographic and clinical characteristics of participants are shown in Table 1. Overall, the mean age was 64 years, with 187 (59%) men. The prevalence of hypertension was higher in patients with long COVID, other comorbidities were not different for the two groups. Both patient groups had similar oxygen therapy requirement, admission to ICU, inflammatory markers, and CT-scan abnormalities. Patients reported 5 (IQR: 3-6) symptoms at the admission. Hyperthermia (79.1%), cough (70.6%), dyspnea (68%), myalgia (50.6%) were mainly reported. Participants were assessed a median of 115 days after hospital discharge. The most frequent persistent symptoms were dyspnea (39.2%) and asthenia (37.1%). Distribution of symptoms is shown figure 1.

In univariate analysis, women had significantly increased risk (OR = 1.89 95% CI [1.16-3.03], p=0.01) than men. Patient with hypertension (OR = 1.64 95% CI [1.04-2.61], p=0.04) experienced persistent symptoms more frequently. The number of initial symptoms (OR = 1.27 95% CI [1.12-1.45], p<0.001) or patient with five or more initial symptoms showed greater risk for long-COVID-19 (OR = 2.47 95%CI [1.12-3.03]).

In multivariate logistic regression, female sex (OR = 1.94 95% CI [1.17-3.22], p=0.01) hypertension (OR = 2.01 95% CI [1.22-3.31], p<0.01) and the number of initial symptoms (OR = 1.35 95% CI [1.17-1.54], p<0.001) remained significantly associated with persistent symptoms (supplementary Table 1). Similarly, in multivariate Poisson regression, the number of persistent symptoms was significantly associated with the number of initial symptoms

75 (adjusted incidence rate ratios, aIRR = 1.16 95% CI [1.11-1.22], p<0.001) as well as female sex  
76 (aIRR = 1.56 95% CI [1.29-1.87], p<0.001), hypertension (aIRR = 1.23 95% CI [1.02-1.50],  
77 p=0.03) and length of stay in hospital (aIRR = 1.01 95% CI [1.005-1.017], p<0.001)

## 78 **Discussion**

79 In our prospective cohort study, female sex, hypertension, and high number of initial  
80 symptoms increased the risk of long covid, and the number of persistent symptoms  
81 independently of acute disease severity and clinical course in hospitalized patients.

82 Our study is in line with reports suggesting that the prevalence of long covid is higher in  
83 women compared with men (Bai et al. 2021; Blomberg et al. 2021; Carvalho et al. 2021;  
84 Huang et al. 2020; Munblit et al. 2021; Wynberg et al. 2021). After detailed analysis of  
85 comorbidities we showed that hypertension was the most significant risk factor for long  
86 COVID-19. Number of initial symptoms had already been described as risk factor of  
87 persistent symptoms, in ambulatory (Sudre et al. 2021), and in hospitalized patient  
88 (Fernández-de-Las-Peñas et al. 2021; Peghin et al. 2021), results that are confirmed here in  
89 this large prospective cohort. Interestingly, severity of acute COVID-19 infection evaluated  
90 by oxygen requirement, inflammatory response, or CT-scan findings was not associated with  
91 persistent symptoms. Our study suggest that long-term burden of COVID-19 involve multiple  
92 non-respiratory symptoms, and was not associated with acute severity or related post-  
93 intensive care syndrome. Strengths of this study are the completeness of data including  
94 objective markers of disease severity and reliable symptoms collection by face-to-face  
95 interview during medical assessment. Our study included sufficient severe forms of COVID-  
96 19 with more than a third of ICU admission's cases, and infectious or thrombotic  
97 complications. This study has several limitations: first, only hospitalized patient alive at  
98 follow up were analysed and we might not have captured enough discharged patients;

99 second, we performed follow-up visits in a single university center, results might not reflect  
100 all hospitalized patient.

101 Identification of risk factors associated with long COVID could be used to target early  
102 intervention and developments to support rehabilitation.

103 **Ethical Approval:**

104 This Research was approved by the Ethics Review committee of the CHU AMIENS-Picardie.

105 **Declaration of Competing Interest:**

106 The authors declare no conflict of interest

107 **Funding source statement:**

108 None

## References

Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mulè G, et al. Female gender is associated with “long COVID” syndrome: a prospective cohort study. *Clinical Microbiology and Infection* 2021 Nov 9 [Online ahead of print] doi.org/10.1016/j.cmi.2021.11.002

Blomberg B, Mohn KG-I, Brokstad KA, Zhou F, Linchausen DW, Hansen B-A, et al. Long COVID in a prospective cohort of home-isolated patients. *Nat Med* 2021 Sep;27(9):1607-1613. doi: 10.1038/s41591-021-01433-3

Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. *Clin Microbiol Infect.* 021 Feb;27(2):258-263. doi: 10.1016/j.cmi.2020.09.052

Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, et al. Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study. *J Infect.* 2021;83(2):237-279. doi:10.1016/j.jinf.2021.04.036

Halpin, SJ, McIvor, C, Whyatt, G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *J Med Virol.* 2021; 93: 1013–1022. doi.org/10.1002/jmv.26368

Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet*, 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8


Munblit D, Bobkova P, Spiridonova E, Shikhaleva A, Gamirova A, Blyuss O, et al. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19. *Clin Exp Allergy.* 2021 Sep;51(9):1107-1120. doi: 10.1111/cea.13997.

Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. *Clin Microbiol Infect.* 2021 Oct;27(10):1507-1513. doi: 10.1016/j.cmi.2021.05.033

Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. *Nat Med.* 2021 Apr;27(4):626-631. doi: 10.1038/s41591-021-01292-y

Wynberg E, van Willigen HDG, Dijkstra M, Boyd A, Kootstra NA, van den Aardweg JG, et al. Evolution of COVID-19 symptoms during the first 12 months after illness onset. *Clinical Infectious Diseases* 2021 Feb;27(2):258-263. doi: 10.1016/j.cmi.2020.09.052





**Figure1: Prevalence of persistent symptoms.**

A: Distribution of persistent symptoms according to the number of initial symptoms (0 - 3: n=96; 4 - 7: n=198; >7: n=22)

B: Distribution of persistent symptoms according to the severity of acute COVID-19 (no oxygen: n=39; ward patients: n= 135 patients; ICU patients: n=142)

	Overall (n=316)	No persistent symptoms (n=115)	Persistent symptoms (n=201)	p-value
<b>Characteristics</b>				
Age (years)	64.1 ± 14.3	64.7 ± 13.7	63.8 ± 14.7	0.62
>65 years old	156 (49.4)	60 (52.2)	96 (47.8)	0.45
Female	129 (40.8)	36 (31.3)	93(46.3)	0.01
Body Mass Index (kg/m <sup>2</sup> )	30.27 ± 6.6	29.9 ± 7.0	30.4 ± 6.2	0.45
Obesity >30 kg/m <sup>2</sup>	147 (47)	48 (42.5)	99 (49.5)	0.23
<b>Comorbidities</b>				
Hypertension	165 (52.2)	51 (44.3)	114 (56.7)	0.03
Diabetes	85 (26.9)	34 (29.6)	51 (25.4)	0.42
Smoking	119 (37.7)	48 (41.7)	71 (35.3)	0.28
Chronic cardiovascular disease	97 (30.7)	38 (30.0)	59 (29.4)	0.49
Chronic lung disease	68 (21.5)	26 (22.6)	42 (20.9)	0.72
Chronic kidney failure	17 (5.4)	7 (6.1)	10 (5.0)	0.67
Neoplasia	12 (3.8)	5 (4.3)	7 (3.5)	0.70
Other (pregnancy, hepatic or neurologic diseases, immunocompromised)	57 (18.0)	15 (13.0)	42 (20.9)	0.11
<u>Number of comorbidities</u>	2 (1-3)	2 (0-3)	2 (1-3)	0.62
0	67 (21.2)	30 (26.1)	37 (18.4)	0.27
1 or 2	134 (42.4)	46 (40)	88 (43.8)	-
3 or more	115 (36.4)	39 (33.9)	76 (37.8)	-
<b>Chronic treatments</b>				
Corticosteroids	17 (5.4)	6 (5.2)	11 (5.5)	0.92
Immunosuppressive therapy	21 (6.6)	11 (9.6)	10 (5.0)	0.12
ACE inhibitors	68 (21.5)	29 (25.2)	39 (19.4)	0.23
ARB	41 (13)	11 (9.6)	30 (14.9)	0.17
Beta-blocker	66 (20.9)	20 (17.4)	46 (22.9)	0.25
Metformin	50 (15.8)	21 (18.3)	29 (14.4)	0.37
<b>Disease severity</b>				
<u>Numbers of initial symptoms</u>	5 (3-6)	4 (3-5)	5 (4-6)	0.006
0-4	145 (45.9)	69 (60)	50 (24.9)	<0.001
5 or more	171 (54.1)	46 (40)	151 (75.1)	<0.001
ICU admission	115 (36.4)	41 (35.7)	74 (36.8)	0.84
<u>Oxygen requirement</u>				
None	39 (12.3)	17 (14.8)	22 (10.9)	0.38
O <sub>2</sub> <4l/min	135 (42.7)	47 (40.9)	88 (43.8)	0.57
O <sub>2</sub> >4l/min	50 (15.8)	22 (19.0)	28 (12.4)	0.23
HFNC or NIV	38 (12.0)	16 (13.7)	22 (10.9)	0.45
IMV	53 (16.8)	13 (11.3)	40 (19.9)	0.05
<u>Laboratory results</u>				
Nadir lymphocyte (/mm <sup>3</sup> )	804 ± 385	795 ± 395	814 ± 379	0.68
Lymphopenia <750/mm <sup>3</sup>	158 (50.9)	63 (55.3)	95 (48.5)	0.25
CRP max (mg/L)	140 ± 94	139 ± 94	142 ± 96	0.76
CRP > 150mg/L	122 (39.1)	44 (38.9)	78 (39.2)	0.96
<u>Lung parenchymal involvement at CT-scan</u>				0.46
No parenchymal abnormalities	18 (7.1)	10 (10.4)	8 (5.1)	
<25%	95 (37.5)	34 (35.4)	61 (38.9)	
25-50%	81 (32.0)	30 (31.3)	51 (32.5)	
>50%	59 (23.3)	22 (22.9)	37 (23.6)	
<b>Clinical course</b>				
<u>Length of stay in hospital in days (IIQ)</u>	10 (6-19)	11 (6-16)	10 (6-21)	0.84
1-6	88 (27.8)	35 (30.4)	53 (26.4)	0.44
7 or more	228 (72.2)	80 (69.6)	148 (73.3)	-
Infectious complications	57 (18)	17 (14.8)	40 (19.9)	0.26
Thrombotic complications	23 (7.3)	8 (7.0)	15 (7.5)	0.87
<b>Follow-up</b>				
Time from symptom onset to follow up in days,	121 (109-139)	121 (110-137)	120 (109-140)	0.78

Time from hospitalization admission to follow up (days)	115 (103-130)	115 (104-130)	114 (102-131)	0.48
<u>Persisting symptoms:</u>				
Asthenia	121 (38.3)		121 (60.2)	
Myalgia	16 (5.1)		16 (8)	
Chest pain	14 (4.4)		14 (7.0)	
Cough	19 (6.0)		19 (9.5)	
Dyspnea	124 (39.2)		124 (61.7)	
Anosmia/dysosmia	20 (6.3)		20 (10.0)	
Ageusia/dysgeusia	15 (4.7)		15 (7.5)	
Headache	7 (2.2)		7 (3.5)	
Concentration disorder	32 (10.1)		32 (15.9)	
Anxiety/irritability	29 (9.2)		29 (14.4)	
Alopecia	20 (6.3)		20 (10.0)	
<u>Lung parenchymal involvement at CT-scan</u> ♂				
No parenchymal abnormalities	122 (40.7)	48 (43.2)	74 (39.2)	0.33
<25%	127 (42.4)	47 (42.3)	80 (42.3)	
25-50%	42 (14.0)	15 (13.5)	27 (14.3)	
>50%	9 (3.0)	1 (0.9)	8 (4.2)	
HAD-A score	6.7 ± 4.3	4.7 ± 3.4	7.5 ± 4.3	<0.001
HAD-D score	5.2 ± 5.1	2.8 ± 3.5	6.4 ± 5.4	<0.001

**Table 1: Demographic and clinical characteristics of enrolled patients according to persistent COVID symptoms.**

Abbreviations are: ACE: Angiotensin Convertase Enzyme; ARB: angiotensin II Receptor Blocker, ICU: Intensive Care Unit, CRP: C-reactive protein, HNFC: High Flow Nasal Cannula for oxygen therapy, IMV: invasive mechanical ventilation. ♂: 300 patients. HAD: Hospital Anxiety and Depression Scale a subscale score (A or D) ≥11 denotes anxiety or depression  
Quantitative variables are presented as mean ± standard deviation or median (interquartile Range), categorical variables are presented as absolute numbers (percentages).